Artus Therapeutics Inc Profile last edited on: 7/28/2022
CAGE: 8HRJ4
UEI: QANFCCHEKUE7
Business Identifier: NO Business Identifier is currently available for this company. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 07
County: Suffolk
Congr. District: 07
County: Suffolk
Public Profile
A pre-clinical stage company, Artus Therapeutics is structured around developing first-in-class therapeutics for inflammatory and metabolic diseases by targeting barrier dysfunction with an initial focus on inflammatory bowel disease. Currently housed in the Harvard Pagliuca Life Lab, the company offers a unique drug design and development platform that - it is suggested - has the potential to transform the treatment paradigm for barrier dysfunction diseases, enabling patients to maintain a healthy gut barrier.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 1 | NIH | $249,998 | |
| Project Title: First-in-class small molecules that enhance lung barrier function during acute respiratory distress syndrome (ARDS) as potential therapeutics for COVID-19 | ||||
| 2021 | 1 | NIH | $251,191 | |
| Project Title: First-in-class small molecule therapeutics to enhance gut barrier function in inflammatory bowel disease | ||||
Key People / Management
Frederick M Ausubel -- President and Co-Founder
Sakthi Jagadeesan -- Co-Founder and CEO
Falgun Parande -- Research Associate
Sakthi Jagadeesan -- Co-Founder and CEO
Falgun Parande -- Research Associate
Company News
There are no news available.
